Enanta Pharmaceuticals Inc (ENTA)

[InefficientMarket]

With tax loss selling season over, let's see if we get a stock price bounce in next couple weeks. If not, no real reason to think a turn around will happen until the partner/sell/refinance occurs. I am not willing to take that risk now.

Appreciate the thoughts but other than cash your analysis effectively discounts all other assets such as retained royalties and Zelicapavir - just to name two. If you’re not willing to “take the risk now” in what situation would you ever be comfortable investing in a biotech if that is your investment risk threshold?

I do concur with your thoughts regarding the litigation. I think the Judge got it right and prefer they walk away from this case because appeals can also be very expensive. In my opinion, It was never a strong case to begin with. Think the following passage is the most difficult to overcome on appeal: the “Court cannot say that substituting a C1 for a C2 alkyl is sufficiently minor that the Court even has the authority to make this correction because the parties do not dispute that if Enanta’s patent only covered C2 alkyls, that range would not cover nirmatrelvir as Enanta contends that nirmatrelvir contains a “—NHC(O)-C1 alkyl” which is a “—NHC(O)-C1-C12-alkyl.”

Happy New Year to all who contribute here - will go back to lurking now.